Compare STE & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STE | PODD |
|---|---|---|
| Founded | 1985 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.9B | 22.1B |
| IPO Year | 1992 | 2007 |
| Metric | STE | PODD |
|---|---|---|
| Price | $263.47 | $304.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $268.25 | ★ $359.00 |
| AVG Volume (30 Days) | 653.3K | ★ 765.6K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 0.96% | N/A |
| EPS Growth | ★ 59.39 | N/A |
| EPS | ★ 6.97 | 3.45 |
| Revenue | ★ $5,702,415,000.00 | $2,521,800,000.00 |
| Revenue This Year | $9.24 | $32.55 |
| Revenue Next Year | $6.30 | $20.39 |
| P/E Ratio | ★ $37.76 | $88.24 |
| Revenue Growth | 7.08 | ★ 27.11 |
| 52 Week Low | $200.98 | $230.05 |
| 52 Week High | $268.60 | $354.88 |
| Indicator | STE | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 59.06 | 40.94 |
| Support Level | $256.68 | $303.20 |
| Resistance Level | $268.60 | $317.34 |
| Average True Range (ATR) | 4.64 | 13.12 |
| MACD | -0.69 | -2.82 |
| Stochastic Oscillator | 65.59 | 3.14 |
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.